![]() 14, 2017 /PRNewswire/ - Otsuka Pharmaceutical Co., Ltd. The system provides an objective summary of drug ingestion over time, to help enhance collaboration with healthcare providers who treat patients with certain serious mental illnesses(1),(2),(3) In addition, it can collect data on activity level, as well as self-reported rest and mood which, with patient consent, can be shared with the healthcare provider and selected members of the family and care team(1) The system records medication ingestion and communicates it to the patient and healthcare provider. The ABILIFY MYCITE System includes: ABILIFY MYCITE, the MYCITE® Patch (wearable sensor) the MYCITE APP (a smartphone application) and web-based portals for healthcare providers and caregivers(1) ABILIFY MYCITE (aripiprazole tablets with sensor) is a drug-device combination product comprised of Otsuka's oral aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. FDA Approval Of A Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor) Otsuka And Proteus® Announce The First U.S.
0 Comments
Leave a Reply. |